Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"DiCE Molecules Announces $80 Million Series C Financing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"DiCE Molecules Announces $60 Million Series C-1 Financing","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"DICE Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$345.0 million","upfrontCash":"Undisclosed","newsHeadline":"DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$2,400.0 million","upfrontCash":"$2,400.0 million","newsHeadline":"Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$2,400.0 million","upfrontCash":"$2,400.0 million","newsHeadline":"Lilly Completes Acquisition of DICE Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by DICE Therapeutics

    Menu

    DICE Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              DICE Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly Completes Acquisition of DICE Therapeutics

              Details:

              Through the acquisition, Lilly expand its immunology pipeline by including, DICE therapeutics' oral IL-17 inhibitors, DC-806 and DC-853. DC-806 is an oral small molecule and a validated drug target for the treatment of autoimmune and inflammatory diseases, including psoriasis.

              Lead Product(s): DC-806

              Therapeutic Area: Dermatology Product Name: DC-806

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $2,400.0 million Upfront Cash: $2,400.0 million

              Deal Type: Acquisition August 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DICE Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

              Details:

              Through the acquisition, Lilly expand its immunology pipeline by including, DICE therapeutics' oral IL-17 inhibitors, DC-806 and DC-853. DC-806 is an oral small molecule and a validated drug target for the treatment of autoimmune and inflammatory diseases, including psoriasis.

              Lead Product(s): DC-806

              Therapeutic Area: Dermatology Product Name: DC-806

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $2,400.0 million Upfront Cash: $2,400.0 million

              Deal Type: Acquisition June 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DICE Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

              Details:

              Company expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates including DC-806.

              Lead Product(s): DC-806

              Therapeutic Area: Dermatology Product Name: DC-806

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: BofA Securities

              Deal Size: $345.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering October 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DICE Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DICE Announces Pricing of Upsized Public Offering of Common Stock

              Details:

              Company expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates including DC-806.

              Lead Product(s): DC-806

              Therapeutic Area: Dermatology Product Name: DC-806

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: BofA Securities

              Deal Size: $300.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering October 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DICE Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

              Details:

              DC-806 is well tolerated with an excellent safety profile across all dose groups in healthy volunteers and psoriasis patients with a robust PK profile and clear pharmacodynamic effects on two distinct biomarkers at both high and low doses of DC-806.

              Lead Product(s): DC-806

              Therapeutic Area: Dermatology Product Name: DC-806

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DICE Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

              Details:

              DC-806 is an orally-available, small molecule antagonist of the pro-inflammatory cytokine, interleukin-17 (IL-17), which is a validated drug target for the treatment of a variety of autoimmune and inflammatory diseases, including psoriasis.

              Lead Product(s): DC-806

              Therapeutic Area: Dermatology Product Name: DC-806

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DICE Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for the Treatment of Psoriasis

              Details:

              S011806 is an orally available, small molecule antagonist of the pro-inflammatory signaling molecule IL-17, an immune cell-derived cytokine that is produced in response to infection by certain microorganisms.

              Lead Product(s): S011806

              Therapeutic Area: Dermatology Product Name: S011806

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DICE Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DiCE Molecules Announces $60 Million Series C-1 Financing

              Details:

              Proceeds of the financing are expected to be used to support advancement of the Company’s preclinical IL-17 antagonist, S011806 into clinical development, advancement of preclinical α4ß7 and αVß1/αVß6 integrin programs, pipeline expansion and other general corporate purposes.

              Lead Product(s): S011806

              Therapeutic Area: Dermatology Product Name: S011806

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: RA Capital Management

              Deal Size: $60.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing August 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DICE Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DiCE Molecules Announces $80 Million Series C Financing

              Details:

              Financing proceeds will support the progression of the Company’s first-in-class, oral IL-17 antagonist into clinical trials and advancement of its PPI antagonist pipeline.

              Lead Product(s): Undisclosed

              Therapeutic Area: Dermatology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: RA Capital Management

              Deal Size: $80.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing January 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY